A direct correlation between nicotinamide N-methyltransferase activity and protein levels in human liver cytosol.

[1]  R. Weinshilboum,et al.  Mouse liver nicotinamide N-methyltransferase: cDNA cloning, expression, and nucleotide sequence polymorphisms. , 1997, Biochemical pharmacology.

[2]  D. Jenden,et al.  Elevation of cerebrospinal fluid choline levels by nicotinamide involves the enzymatic formation of N1-methylnicotinamide in brain tissue. , 1996, Life sciences.

[3]  P. Lance,et al.  n‐Butyrate induces plasminogen activator inhibitor type 1 messenger RNA in cultured Hep G2 cells , 1996, Hepatology.

[4]  P. Little,et al.  Human nicotinamide N-methyltransferase gene: molecular cloning, structural characterization and chromosomal localization. , 1995, Genomics.

[5]  K. Kawajiri,et al.  Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5'-flanking region. , 1994, Journal of biochemistry.

[6]  R. Weinshilboum,et al.  Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. , 1994, The Journal of biological chemistry.

[7]  A. Jones,et al.  The human phenolsulphotransferase polymorphism is determined by the level of expression of the enzyme protein. , 1993, The Biochemical journal.

[8]  R. Stockley,et al.  Use of an enzyme-linked immunosorbent assay to assess penetration of amoxicillin into lung secretions , 1992, Antimicrobial Agents and Chemotherapy.

[9]  D. Nebert,et al.  Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. , 1991, American journal of human genetics.

[10]  R. Weinshilboum,et al.  Thiopurine methyltransferase isozymes in human renal tissue. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[11]  D. Grant,et al.  Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. , 1990, The Journal of clinical investigation.

[12]  C. Szumlanski,et al.  Human liver nicotinamide N-methyltransferase: ion-pairing radiochemical assay, biochemical properties and individual variation. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[13]  R. Weinshilboum.  Pharmacogenetics of methylation: relationship to drug metabolism. , 1988, Clinical biochemistry.

[14]  T. Alston,et al.  Substrate specificity of nicotinamide methyltransferase isolated from porcine liver. , 1988, Archives of biochemistry and biophysics.

[15]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[16]  A. J. Bradbury,et al.  The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety , 1985, Neuroscience Letters.

[17]  A. J. Bradbury,et al.  The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment , 1985, Neuroscience Letters.

[18]  G. Cantoni.  Methylation of nicotinamide with soluble enzyme system from rat liver. , 1951, The Journal of biological chemistry.

[19]  R. Weinshilboum,et al.  Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. , 1996, DNA and cell biology.

[20]  R. Cuomo,et al.  Nicotinamide methylation in patients with cirrhosis. , 1994, Journal of hepatology.

[21]  H. Pall,et al.  N-methylation of pyridines and Parkinson's disease. , 1993, Advances in neurology.

[22]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .